Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Should You Investigate Omnicell, Inc. (NASDAQ:OMCL) At US$31.34?

2025-09-22
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it saw a double-digit share price rise of...

Is Omnicell (OMCL) a Great Value Stock Right Now?

2025-09-18
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

OMCL or HIMS: Which Is the Better Value Stock Right Now?

2025-09-15
OMCL vs. HIMS: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM

2025-09-12
Butterfly Network and Omnicell stand out as top health-tech stocks benefiting from AI, machine learning, and quantum advancements in healthcare, alongside NVIDIA, Palantir, and IBM driving transformative innovations.

Wall Street Analysts Think Omnicell (OMCL) Could Surge 39.36%: Read This Before Placing a Bet

2025-09-11
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Omnicell, Inc. (NASDAQ:OMCL) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

2025-09-05
Omnicell's (NASDAQ:OMCL) stock is up by a considerable 8.6% over the past month. However, we decided to pay attention...

3 Low-Volatility Stocks We Steer Clear Of

2025-09-05
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Omnicell (OMCL): Buy, Sell, or Hold Post Q2 Earnings?

2025-09-01
Over the past six months, Omnicell’s stock price fell to $32.30. Shareholders have lost 14.4% of their capital, which is disappointing considering the S&P 500 has climbed by 10.5%. This may have investors wondering how to approach the situation.

Q2 Earnings Highlights: Omnicell (NASDAQ:OMCL) Vs The Rest Of The Healthcare Technology for Providers Stocks

2025-08-28
Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Omnicell (NASDAQ:OMCL) and its peers.

Earnings Estimates Rising for Omnicell (OMCL): Will It Gain?

2025-08-26
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.